Studies of Protein Aggregation in A53T α-synuclein Transgenic, Tg2576 Transgenic, and P246L Presenilin-1 Knock-in Cross Bred Mice
Overview
Affiliations
Synucleinopathies are a group of neurodegenerative disorders, including Parkinson disease, associated with neuronal amyloid inclusions comprised of the presynaptic protein α-synuclein (α-syn); however the biological events that initiate and lead to the formation of these inclusions are still poorly understood. There is mounting evidence that intracellular α-syn aggregation may proceed via a seeding mechanism and could spread between neurons through a prion-like mechanism that may involve other amyloidogenic proteins. Several lines of evidence suggest that Aβ peptides and/or extracellular Aβ deposits may directly or indirectly promote intracellular α-syn aggregation. To assess the effects of Aβ peptides and extracellular Aβ deposits on α-syn aggregate formation, transgenic mice (line M83) expressing A53T human α-syn that are sensitive to developing α-syn pathological inclusions were cross bred to Tg2576 transgenic mice that generated elevated levels of Aβ peptides and develop abundant Aβ plaques. In addition these mice were bred to mice with the P264L presenilin-1 knock-in mutation that further promotes Aβ plaque formation. These mice demonstrated the expected formation of Aβ plaques; however despite the accumulation of hyperphosphorylated α-syn dystrophic neurites within or surrounding Aβ plaques, no additional α-syn pathologies were observed. These studies show that Aβ amyloid deposits can cause the local aggregation of α-syn, but these did not lead to more extensive α-syn pathology.
Lim M, Boschen S, Kurti A, Casey M, Phillips V, Fryer J Biomedicines. 2023; 11(10).
PMID: 37893236 PMC: 10604054. DOI: 10.3390/biomedicines11102863.
Kee T, Espinoza Gonzalez P, Wehinger J, Bukhari M, Ermekbaeva A, Sista A Front Aging Neurosci. 2021; 13:660843.
PMID: 33967741 PMC: 8100248. DOI: 10.3389/fnagi.2021.660843.
What we can learn from animal models about cerebral multi-morbidity.
Baker S, Gotz J Alzheimers Res Ther. 2015; 7(1):11.
PMID: 25810783 PMC: 4373088. DOI: 10.1186/s13195-015-0097-2.
Paumier K, Sukoff Rizzo S, Berger Z, Chen Y, Gonzales C, Kaftan E PLoS One. 2013; 8(8):e70274.
PMID: 23936403 PMC: 3731353. DOI: 10.1371/journal.pone.0070274.
Resende R, Marques S, Ferreiro E, Simoes I, Oliveira C, Pereira C Neurochem Res. 2013; 38(4):797-806.
PMID: 23389658 DOI: 10.1007/s11064-013-0982-7.